New Diagnostic Test for Mesothelioma
Prometheus Laboratories Inc, a pharmaceutical company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care, launched its ProOnc line of cancer diagnostics in October.
The ProOnc diagnostic tests are based on recently developed, highly sensitive microRNA technology. “MicroRNAs are small, non-coding sequences of RNA that are critically important in many biological and pathological processes,” said Harvey Pass, M.D., Professor of Cardiothoracic Surgery and Director of the Division of Thoracic Surgery and Thoracic Oncology at New York University Langone Medical Center and its NYU Cancer Institute. The sensitivity of microRNA diagnostics enables physicians to more confidently differentiate cancers.
The ProOnc MesotheliomaDx utilizes cutting-edge molecular diagnostics using microRNA to differentiate malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.
Prometheus believes that ProOnc TumorSourceDx and ProOnc SquamousDx, as well as ProOnc MesotheliomaDx, will provide cancer specialists with more objective and quantitative results than existing diagnostics leading to more personalized treatments for patients.